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Abstract 
Invasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients, rapid and sensitive detection 
of Aspergillus from clinical samples has been a major challenge in the early diagnosis of IA. An enzyme-linked immu-
nosorbent assay of nucleic acid sequence-based amplification (NASBA-ELISA) was developed to fulfil the need for the 
efficient diagnosis of these infections. The primers targeting 18S rRNA were selected for the amplification of Aspergil-
lus RNA by the isothermal digoxigenin (DIG)-labeling NASBA process. The DIG-labeled RNA amplicons were hybrid-
ized with a specific biotinylated DNA probe immobilized on streptavidin-coated microtiter plate. The hybrids were 
colorimetrically detected by the addition of an anti-DIG antibodies linked to ALP and substrate (disodium 4-nitro-
phenyl phosphate). The detection limit of the Aspergillus NABSA-ELISA system was 1 CFU and the RNA in non-target 
bacteria or fungus was not amplified. The performance of this NASBA-ELISA compared to RT-PCR and galactoman-
nan (GM) was evaluated by testing blood samples from 86 patients at high risk for IA. The sensitivity of NASBA-ELISA, 
RT-PCR and GM-ELISA was 80.56 % (95 % CI 63.98–91.81), 72.22 % (95 % CI 54.81–85.80), 58.33 % (95 % CI 40.76–74.49), 
respectively, and the specificity was 80.00 % (95 % CI 66.28–89.97), 84.00 % (95 % CI 70.89–92.83), 82.00 % (95 % 
CI 68.56–91.42). The efficiency of the three methods in various combinations was also evaluated. Combination of 
NASBA-ELISA and GM-ELISA testing achieved perfect specificity (100 %; 95 % CI 92.89–100) and perfect positive pre-
dictive value (100 %; 95 % CI 83.16–100). The best sensitivity (97.22 %; 95 % CI 85.47–99.93) and the highest Youden 
index (0.652) were obtained by testing with both NASBA and RT-PCR in parallel. In conclusion, the NASBA-ELISA assay 
consists of an alternative process for large-scale samples detection with semi-quantitative results and provides good 
clinical performance without resorting to expensive equipment. This assay makes it possible for the NASBA based 
RNA diagnosis to become a routine work in laboratories in less developed countries with fewer resources.
Keywords: NASBA-ELISA, RT-PCR, GM-EIA, Invasive aspergillosis
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Introduction
Invasive aspergillosis (IA), an opportunistic fun-
gal infection, is increasingly recognized as a major 
cause of morbidity and mortality in immunocompro-
mised patients, including those receiving aggressive 
chemotherapy or immunosuppressive drugs (Chan-
drasekar 2010; Barton 2013; Leventakos et  al. 2010). 
Because of its high mortality, early diagnosis is the 
key to successful treatment. However, microbiological 
examination such as Aspergillus culture is time-con-
suming and has lower positive rate (Torelli et al. 2011), 
it is also difficult in distinguishing between infection 
and colonization. Diagnosis by biopsy or histopathology 
is difficult due to the severity of illness in these patients. 
Galactomannan by enzyme immunosorbent assay (GM-
EIA) is one of the standard measures (Yoo et  al. 2007; 
Open Access
*Correspondence:  xiayun12cn@aliyun.com 
1 Department of Laboratory Medicine, the First Affiliated Hospital 
of Chongqing Medical University, Chongqing 400016,  
People’s Republic of China
Full list of author information is available at the end of the article
Page 2 of 9Du et al. AMB Expr  (2016) 6:91 
Boutboul et  al. 2002) and is included as an important 
component of microbiological factors in the diagnostic 
criteria devised by the Mycology Study Group of the 
European Organization for Research and Treatment of 
Cancer (EORTC/MSG) (De Pauw et  al. 2008). Perfor-
mance of GM-EIA can vary considerably and has been 
shown to be affected by various factors, leading to both 
false positive and false-negative results (Mikulska et al. 
2012). Galactomannan is not unique to Aspergillus 
spp., there are cross-reacting antigens in other fungus 
and some antibiotic agents. Antibody detection meth-
ods often cannot distinguish between current and past 
infection and it performs poorly in patients with hae-
matological malignancy or having undergone bone mar-
row or stem cell transplantation.
More recently, nucleic acid amplification tests (NAATs) 
in  vitro can provide increased sensitivity and specificity 
of detection (van der Vliet et  al. 1993; Ieven and Goos-
sens 1997). Nucleic acid sequence-based amplification 
(NASBA) is a molecular method for amplification of 
target RNA segments in which the necessity of thermo 
cycling is excluded due to lack of any thermal variation 
in the reaction environment. The amplification efficiency 
of NASBA is more robust than that of PCR (Mercier-
Delarue et  al. 2014), yielding more than 1012 amplicons 
in as little as 30 min (Zhao et al. 2009). The advantages 
of NASBA have promoted interest in evaluating its appli-
cation to detection of Aspergillus RNA in clinical sam-
ples. The main drawback of NASBA is that special care 
is needed in sample preparation and detection, due to 
the profound susceptibility of RNA to degradation. Thus, 
further studies are warranted to improve the ability to 
quantify pathogen load and develop automated, stand-
ardized protocols for sample processing and data analy-
sis. Conventional NASBA requires several steps after 
RNA amplification, including electrophoresis or blotting 
and hybridization, which are inconvenient for detecting a 
large number of samples in clinical routine. The NASBA-
enzyme-linked immunosorbent assay (NASBA-ELISA) 
consisting of an alternative process for large-scale screen-
ing allows for application in daily life. This technique 
combines an immunological method to quantify the 
NASBA product directly after immobilization of bioti-
nylated DNA on a microplate. The NASBA-ELISA can 
be performed without special equipment and reagents 
for detection of amplified product compared to NASBA-
electrophoresis. Therefore, NASBA-ELISA allows the 
using of RNA based diagnosis for routine purposes in 
poor developed laboratories.
The aim of this work was developing an NASBA- 
ELISA system as an improvement over traditional assays 
to detect Aspergillus 18s RNA in human blood samples 
for diagnosis of invasive aspergillosis. RT-PCR and GM 
test were performed simultaneously to evaluate the per-
formance of the three methods.
Materials and methods
Fungal and bacterial strains
A. fumigatus strain CMCC A1a, kindly provided by Dr. 
WeiPing Lu (Daping Hospital, Third Military Medi-
cal University of People,  Liberation Army, ChongQing, 
China), was grown on Sabouraud’s dextrose agar at 37 °C 
for 2–3  days. The number of Aspergillus spores diluted 
in saline suspension was quantified using a Neubauer 
chamber, and a solution containing approximately 105 
spores was used for total RNA extraction. Strains of E.coli 
ATCC25922, Candida albicans ATCC64548, Staphy-
lococcus aureus ATCC29213, Pseudomonas aeruginosa 
ATCC27853 and Cryptococcus neoformans FY226 (iso-
lated from clinical samples) were cultured on blood agar 
at 37  °C for 1–2 days. The total RNA from these strains 
was extracted using Trizol reagent (Invitrogen, Cali-
fornia, America) strictly following the manufacturer`s 
instruction.
Patient populations and blood samples
The definitions of invasive fungal infection according to 
the EORTC/MSG (De Pauw et al. 2008) updated criterion 
are classified into “proven”, “probable” and “possible”. To 
define as a proven invasive fungal infection it is required 
that a fungal hyphae or spores be detected by histologi-
cal analysis or in the culture of a specimen obtained by a 
sterile procedure from a normally sterile and clinically or 
radiologically abnormal site consistent with an infectious 
disease process of tissue taken from the infected site of 
the disease. Probable invasive fungal infection requires 
the presence of a host factor, a clinical criterion, and 
symptoms consistent with the disease entity, and myco-
logical evidence including: direct microscopic analysis, 
culture and serologic test such as GM.
Based on this criterion, a total of 36 patients at high 
risk for IA (including 9 proven cases, 27 probable cases) 
were served as test group and 50 patients not achiev-
ing an EORTC/MSG diagnosis criterion were served as 
control group. Cases were selected on the solid basis of 
sample availability and diagnosis, whereas controls were 
randomly selected from a period of testing similar to that 
of the IA cases. All patients were enrolled from January 
2014 to December 2015 in the First Affiliated Hospital of 
Chongqing Medical University, a 3200-bed teaching hos-
pital in Chongqing, southwestern China. Information of 
patients was retrieved from the hospital information sys-
tem and the laboratory information system  (Additional 
file 1). Plasma samples were collected from the samples 
that were sent to our department for (1,3)-β-D-glucan 
and galactomannan detection before any antifungal 
Page 3 of 9Du et al. AMB Expr  (2016) 6:91 
therapy began. Plasma was separated from each fresh 
blood sample by centrifugation at 2500×g, transformed 
to Rnase free tubes and stored at −80 °C for further use.
Aspergillus GM detection
Platelia kits (Bio-Rad Laboratories, Hercules, CA) were 
used to measure the galactomannan level in blood sam-
ples. Assay performance and interpretation of positivity 
were performed by an investigator blinded to case sta-
tus and as directed by the manufacturer. Optical densi-
ties were determined using a threshold index (optical 
density at 450/620  nm [OD450/620] of sample/OD450/620 
of threshold control) with the Sunrise Microplate Reader 
(Tecan, Männedorf, Switzerland). Samples were run with 
positive, negative, and threshold controls supplied by the 
manufacturer. Optical density index was calculated as the 
optical density of the sample divided by the mean opti-
cal density of 2 threshold controls. On these grounds, any 
value above 0.5 was considered positive.
RNA extraction
In terms of determining analytical sensitivity the 
NASBA-ELISA assays, briefly, fungal spores suspensions 
of a certain concentration (106/ml, 105/ml, 104/ml, 103/
ml) were prepared by microscope count method using 
Neubauer’s hemacytomete. 100  μL portions of fungal 
suspensions which had been grinded in mortar (free of 
Rnase) with liquid nitrogen were used for RNA extrac-
tion by total RNA rapid extraction kit. In terms of clinical 
application on the NASBA-ELISA, 200 μL of plasma sam-
ples (restored to room temperature from −80  °C) were 
used for RNA extraction by the same kit as above. The 
above samples mixed 300 μL of RLS lysis buffer followed 
by incubation for 10 min at room temperature. The tubes 
were vortexed vigorously for 15 s and then incubated for 
3 min after addition of 150 μL chloroform. The aqueous 
phase was transferred to a spin column AC and mixed 
with 500 μL of 70 % ethanol, followed by  centrifugation 
at 12,000×g for 10  min at 4  °C. The RNA was washed 
sequentially with buffer RE and buffer RW. Finally, 60 μL 
eluate was obtained and stored at −80  °C until further 
use. (low concentration of RNA was obtained through 
tenfold serial dilutions of RNA extracted with high con-
centrations of spores).
Primers and probe
A primer pair encoding a highly conserved 18S rRNA 
region specific for the Aspergillus genus was chosen as 
previously reported to amplify a 243 nucleotide frag-
ment of the target RNA that includes the species-specific 
region for oligonucleotide probe to identify the Aspergil-
lus spp. (Loeffler et al. 2001). The reverse primer (Prim-
ers1.2) bears the bacteriophage T7 RNA polymerase 
promoter binding region and preferred transcriptional 
initiation sequence at its 5′ end. A biotinylated oligonu-
cleotide probe (hybridization probe) corresponding to an 
internal region defined by the primers was synthesized 
for the detection of amplified target RNA (Table 1).
Reverse transcriptase PCR (RT‑PCR) process
Reverse transcription was performed in an ABI Veriti™ 
96-Well Thermal Cycler (Applied Biosystems; Life Tech-
nologies, Carlsbad, CA, USA) with a total reaction vol-
ume of 20  μL per well containing 4  μL 5×  PrimeScript 
buffer, 1 μL PrimeScript Enzyme Mix × 1, 1 μL Oligo DT 
primer (50 μm), 1 μL random 6 mers (100 μm), 5 μL tem-
plate RNA, 8 μL Rnase water. Thermal cycling conditions 
were 37 °C for 15 min, followed by 85 °C for 5 s and 4 °C 
for 5  s and the cDNA product was as template of PCR 
described below.
PCR reagents in a final volume of 25 μL included: 2 μL 
template cDNA, 12.5 μL Taq DNA polymerase (5 U/μL), 
1  μL of each primer (10  pmol/μL, the same as NASBA 
primers), 3.5 μL dH2O. The PCR program was carried out 
at 95 °C for 10 min, followed by 35 cycles of 30 s at 95 °C 
and 30  s at 72  °C. The final extension was at 72  °C for 
5  min. PCR products were electrophoresed in 1  % aga-
rose followed by staining with Goldview then visualized 
under ultraviolet light, and the results were recorded by 
photography.
Digoxigenin (DIG)‑labeling NASBA process
For DIG-labeling NASBA reaction, Aspergillus RNA 
sample (5  μL) was suspended in 10  μL of amplification 
Table 1 Nucleotide sequences of oligonucleotide primers and probe used in this study
a Underlining indicates the T7 promoter region
Primers/probe Sequence (5′‑3′) Length (bp)
Primers 2.1 5′-GCCGCGGTAATTCCAGCTCCAATA-3′ 24
Primers 1.2 + T7a 5′-AATTCTAATACGACTCACTATAGGGGAGCAAAGGCCTGCTTTGAACA-3′ 47
Hybridization probe Bioth-GGTCCGCCTCACCGCGAGTACTG-3′ 20
NASBA product 243
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reagent solution containing 2  mmol/L each NTP, 
0.2  mmol/L Digoxigenin-11-UTP, 1.6  mmol/L each 
dNTP, 40  mmol/L Tris–HCl (pH 8.5), 70  mmol/L KCl, 
5 mmol/L dithiothreitol, 12 mmol/L MgCl2, 0.375 mol/L 
sorbitol, 12  U ribonuclease inhibitor (Promega, Fitch-
burg, WI, USA), 0.4 μmol/L each primer, followed by an 
incubation at 65  °C for 5  min and at 41  °C for another 
5 min. Then, 5 μL enzyme mixture (40U T7 RNA poly-
merase (Promega), 2.0  μg bovine serum albumin, 
8U avian myelo-blastosis virus reverse transcriptase 
(Takara Bio), and 0.1 U RNase H) was added. The reac-
tion mixture was incubated for 90 min at 41  °C for iso-
thermal amplification. Negative controls consisted of all 
of the same reagents but substituting for the target with 
an equal volume of buffer. The amplification products 
were analyzed by 1 % agarose gel electrophoresis (Wang 
et  al. 2014; Mollasalehi and Yazdanparast 2013), and by 
NASBA-ELISA DIG detection system described below.
Microtiter plate hybridization and detection of NASBA 
product
Biotinylated probe (Hybridization probe) (0.1  mM, 
100 μL) diluted in PBST buffer (phosphate-buffered saline 
containing 0.05  % (v/v) TWEEN-20, PH 7.2, prepared 
with DEPC water) was incubated in the streptavidin-
coated microtiter plate (restored to room temperature 
from 4  °C, Haili, JiangSu, China) at room temperature 
for 1 h with gentle agitation. After aspiration, the plates 
were washed with 3  ×  300  μL PBST buffer to prepare 
for assay application (Gill et al. 2006). For hybridization, 
10  μL DIG-labeled NASBA product was heated 2  min 
at 95  °C to inactive Rnase H activity and mixed with 90 
μL hybridization solution (50  mM sodium-phosphate 
buffer, pH 7.0, prepared with DEPC water). The mixture 
(100 μL) was added to the oligoprobe-coated streptavidin 
microtiter plate and incubated for 1 h at 37 °C with gentle 
shaking. The plates were washed with 3 × 300 μL PBST 
buffer. Anti-digoxigenin antibody ALP conjugate (Roche, 
Basel, Switzerland) diluted 500-fold in PBST buffer was 
added to each well in a final volume of 100 μL and the 
microtiter plates were incubated for 30  min at 37  °C. 
After five washes with PBST solution, 100  μL of devel-
oper PNPP (restored to room temperature from −20 °C, 
Yeasen, Shanghai, China) was added to each well and 
incubated in the dark at 37 °C for 15 min. Finally, 50 μL 
of stop solution was added and the developed color was 
measured at 405 nm in a microtiter plate reader (Ravan 
and Yazdanparast 2012; Gomes et al. 2010; Di Pinto et al. 
2012). All experiments were performed in triplicate with 
negative controls, and data represent mean values. The 
cut-off value was calculated as the mean absorbance 
value of the negative controls plus three standard devia-
tions, as obtained with a single NASBA-ELISA test. As 
the mean absorbance value and standard deviation were 
0.059 ± 0.012, a sample was considered positive when the 
absorbance of the three measurements was greater than 
0.095 (the cut-off value).
Statistical analysis
Performance parameters for each approach were ana-
lyzed by the MedCalc® 15.2.2 and SPSS22.0. Positive 
results from patients with proven or probable IA accord-
ing to the EORTC/MSG criteria were considered to be 
true positives and used to calculate the sensitivity of the 
three assays. For calculation of specificity, negative results 
from patients without EORTC/MSG evidence of IA were 
considered to be true negatives. Receiver operating char-
acteristic curve (ROC) was used to assess the diagnostic 
value of NASBA-ELISA system. A higher value of area 
under the curve (AUC) represents a greater diagnostic 
value of the assay. Comparison between two methods 
was performed by paired diagnosis test design using 
Fisher’s exact test to generate two-sided P values with a 
P value of ≤0.05 being considered significant. Absorb-
ance readings and arithmetical means of the number of 
Aspergillus spores (transformed into log scale) were ana-
lyzed by Pearson’s parametric correlation coefficient or 
Spearman’s nonparametric correlation coefficient in the 
NASBA-ELISA test. The Youden index was calculated 
to evaluate the synthetic ability of each assay. A kappa 
statistic was determined and interpreted as described 
previously. Values greater than 0.8 means excellent agree-
ment between methods, values of 0.61–0.8 means sub-
stantial agreement, values of 0.41–0.6 means moderate 
agreement, and values below 0.4 means poor agreement 
(White et al. 2013).
Results
Analytical sensitivity of the NASBA process and analytical 
sensitivity of the NASBA‑ELISA with DIG detection system
Analytical sensitivity of NASBA by using 1 % agarose gel 
electrophoresis was obtained by 10-fold serial dilutions of 
genomic RNA (Fig. 1). The limit of detection was 1 CFU.
The efficiency of the NASBA-ELISA was proved by 
analyzing two fold serial dilutions of digoxigenin-labeled 
NASBA amplicons of Aspergillus. The OD increased 
with the increasing concentration of amplification prod-
ucts within a certain range (Fig. 2). Tenfold serial diluted 
concentrations of nucleic acid sample RNA extracted 
from a saline solution containing 105 CFU Aspergillus 
spores were employed to determine the sensitivity of the 
developed method. As the OD405 values for 1–105  CFU 
were above the cut-off threshold value of 0.095 (Fig.  3), 
the lowest detection was 1  CFU, as the same as that 
obtained by 1  % agarose gel electrophoresis. The poly-
nomial fitting between the optical density readings of 
Page 5 of 9Du et al. AMB Expr  (2016) 6:91 
the NASBA-ELISA and the log number of the template 
spores was significant, with the determination coefficient 
of 0.986 (Fig. 4).
Analytical specificity of the NASBA‑ELISA with DIG 
detection system
Experimental specificity was assessed by amplifying non-
target RNA extracted from E. coli, C. albicans, C. neo-
formans, S. aureus and P. Aeruginosa. The amplification 
products were analyzed by ELISA. No positive results 
were demonstrated for these strains, indicating that the 
assay is highly specific for Aspergillus (Fig. 5).
Tests results of patients
The results of NASBA-ELISA, RT-PCR and GM-ELISA 
assays were listed in Table 2. The NASBA-ELISA OD val-
ues were assessed by ROC analysis (Fig.  6). Area under 
the curve = 0.760(95 % CI 0.650–0.870). The diagnostic 
parameters were calculated for each method (Table  3). 
Comparison of the three assays revealed that NASBA-
ELISA had the highest sensitivity, at 80.56  % (95  % CI 
63.98–91.81), and RT-PCR had the highest specificity, 
at 84.00  % (95  % CI 70.89–92.83). Hypothesis testing 
revealed that sensitivity of NASBA-ELISA was signifi-
cantly greater than that of GM-ELISA (P  =  0.023) and 
Fig. 1 Analytical sensitivity of NASBA followed by 1 % agarose gel 
electrophoresis with Goldview for tenfold serial dilutions of genomic 
RNA extracted from a saline solution containing 105 CFU Aspergillus 
spores. Lane 1 105 CFU; lane 2 104 CFU; lane 3 103 CFU; lane 4 102 CFU; 
lane 5 10 CFU; lane 6 1 CFU; lane 7 0.1 CFU; lane 8, negative control. 





























Fig. 2 Detection of DIG-labeled NASBA products by the microplate 
hybridization system. NASBA was performed in the presence of 
105 CFU Aspergillus spores and then NASBA product was twofold seri-
ally diluted before DIG-detection ELISA system (filled square). Negative 
control consists of NASBA reaction performed in the absence of 
























Fig. 3 Sensitivity of the NASBA-ELISA for molecular detection of 
Aspergillus 18S rRNA. Tenfold serial dilutions of Aspergillus (105 CFU) 
were prepared and used for 18S rRNA extraction and DIG-labeling 
NASBA amplification.Then 5 μL of the NASBA product was used in 
DIG-detection NASBA-ELISA system. Each dilution was analyzed in 
duplicate
Fig. 4 Correlation between log-transformed individual measure-
ments of Aspergillus spores and absorbance readings. The deter-
mination coefficient between NASBA-ELISA OD and log[spores 
concentration] was 0.986
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no other significant differences were observed among 
the three tests. In addition, the NASBA-ELISA assay had 
the best performance in negative predictive value, and 
Youden index, while RT-PCR was the best performing 
assay for positive likelihood ratio and positive predictive 
value. Optimal performance was achieved by comparing 
the performance of various combinations of the three 
tests (Table  4, the last page). Perfect specificity (100  %; 
95  % CI 92.89–100) and perfect PPV (100  %; 95  % CI 
83.16–100) were attainable by combining NASBA-ELISA 
with GM-EIA in serial testing. Combining NASBA-
ELISA with RT-PCR appeared to be better than other 
combinations for sensitivity, NPV and Youden index.   
Discussion
Invasive aspergillosis (IA) is recognized as an opportun-
istic infection among many categories of immunocom-
promised patients (Nabili et al. 2013) and continues to be 
problematic to diagnose due to the lack of rapid, specific, 
and sensitive diagnostic methods. The use of NASBA has 
been reported rarely to detect Aspergillus species (Dimo-
poulos et  al. 2012). We developed an NASBA-ELISA 
assay for analyzing Aspergillus RNA in plasma sample to 
rapidly diagnose IA. ELISA techniques provide an alter-
native to gel electrophoresis for the detection of NASBA 
products.
Evaluation of the analytical sensitivity of the Aspergil-
lus NASBA-ELISA system showed the same sensitive as 
NASBA-electrophoresis with the lowest detection con-
centration of 1 CFU. The high sensitivity of the method is 
due to two factors: (1) The target of NASBA-ELISA assay, 
18rRNA, is present at a level of approximately 100–300 
copies in per fungal cell (Park et  al. 2011); (2) The Bio-
tin-Avidin-System (BAS) used for immobilization of 
amplification products on microtiter plates increases the 
sensitivity of procedure by taking advantage of its multi 
stage amplification effect.
The NASBA-ELISA system was developed by using 
primers designed by Loeffler J et al. (2001), who proved 
specificity of the primers and the use of bioth-probe also 
assured fine specificity for Aspergillus genus. The speci-
ficity was also proved by the non-specific amplification 
signal when non-target RNA was used as templates in 


















Fig. 5 Analysis of specificity of the NASBA-ELISA DIG-detection 
system. NASBA-ELISA was performed with non-target nucleic acids. 
NASBA-ELISA was performed on 18S rRNA of A.fumigatus as a positive 
control. DIG-detection ELISA was performed on H2O as a negative 
control. The results are means of triplication analysis
Table 2 Assay concordance on a patient basis




No IA  
(n = 50)






NASBA-ELISA, GM positive 2 0
RT-PCR, GM positive 1 1
NASBA-ELISA positive 7 7
RT-PCR positive 5 5
GM positive 0 8
NASBA-ELISA, RT-PCR, GM 
negative
1 26
Fig. 6 ROC curve of the NASBA-ELISA assay. The ROC analysis is 
based on optical density values. Area under the curve = 0.760 (95 % 
CI 0.650–0.870). Diagonal segments are produced by ties
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our experiment. Further more, a potential risk of con-
tamination with such non-target microbes nucleic acids 
could be ignored because only the target nucleic acids 
with T7 promoter can be amplified. Thus, the hybridi-
zation signals acquired were comparable in terms of 
intensity to that of Aspergillus alone. As the results indi-
cated, the relation between optical density of ELISA and 
amplification products concentration was given through 
polynomial fitting. Once the ELISA reaction has reached 
saturation, the optical density maybe not be improved 
obviously by increasing concentration of products. 
Therefore, NASBA-ELISA assay can be taken as a semi-
quantitative technique of amplification products analysis.
GM-ELISA is a broadly used routine diagnostic assay and 
has been enrolled as a formal component of diagnostic crite-
ria in EORTC/MSG. Reverse transcriptase PCR (RT-PCR), 
involving treatment with reverse transcriptase enzyme (an 
RNA-dependent DNA polymerase) prior to a normal PCR, 
uses the same template RNA as NASBA. Thus, the diagnos-
tic performance of the NASBA-ELISA was compared to RT-
PCR and galactomannan (GM) by testing plasma samples 
simultaneously with the three methods.
It is known that GM testing frequently appeared false-
positive results and low sensitivity for patients receiving 
preventive medication. A previous study has reported 
that GM is not released into the circulation during infec-
tion until the fungus invaded the endothelial compart-
ment (Hope et  al. 2007). This suggested that circulating 
GM could not be detected until angioinvasion by the fun-
gus occurs. Antibodies to GM could also develop which 
have been suggested as a cause of false negative serum 
GM results in patients with IA (Herbrecht et  al. 2002). 
It has also been reported that some false positive GM 
results derived from the existence of GM in some other 
fungies and in preparations of some antibiotic agents 
(Vergidis et al. 2012; Tortorano et al. 2012).
Table 3 Performance parameters for  GM ELISA, Aspergillus RT-PCR, and  Aspergillus NASBA-ELISA when  testing cases 
of proven/probable IA
Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
* P < 0.05 versus NASBA-ELISA
Parameter NASBA‑ELISA RT‑PCR GM‑ELISA
Sensitivity [% (95 % CI)] 80.56 (63.98–91.81) 72.22 (54.81–85.80) 58.33 (40.76–74.49)*
Specificity [% (95 % CI)] 80.00 (66.28–89.97) 84.00 (70.89–92.83) 82.00 (68.56–91.42)
Positive likelihood ratio 4.03 (2.26–7.17) 4.51 (2.32–8.79) 3.24 (1.69–6.23)
Negative likelihood ratio 0.24 (0.12–0.48) 0.33 (0.19–0.57) 0.51 (0.34–0.76)
PPV [% (95 % CI)] 74.36 (57.87–86.96) 76.47 (58.83–89.25) 70.00 (50.60–85.27)
NPV [% (95 % CI)] 85.11 (71.69–93.80) 80.77 (67.47–90.37) 73.21 (59.70–84.17)
Youden index 0.61 0.56 0.40
κ statistic 0.60 0.57 0.41
Table 4 Combined assay performance for GM ELISA, Aspergillus RT-PCR, and Aspergillus NASBA-ELISA when testing cases 
of proven/probable IA
Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
a  “or” indicates that at least one of the assays is required to be positive
b  “and” indicates that both assays are required to be positive before a patient is considered positive












Sensitivity 97.22 (85.47–99.93) 55.56 (38.10–72.06) 83.33 (67.19–93.63) 55.56 (38.10–72.06) 77.78 (60.85–89.88) 52.78 (35.49–69.59)
Specificity 68.00 (53.30–80.48) 94.00 (83.45–98.75) 62.00 (47.17–75.35) 100 (92.89–100) 66.00 (51.23–78.79) 98.00 (89.35–99.95)
Positive likelihood 
ratio
3.04 (2.02–4.57) 9.26 (2.98–28.82) 2.19 (1.50–3.22) Infinity 2.29 (1.50–3.49) 26.39 (3.70–188.24)
Negative likelihood 
ratio
0.04 (0.01–0.28) 0.47 (0.33–0.69) 0.27 (0.13–0.58) 0.44 (0.31–0.64) 0.34 (0.18–0.64) 0.48 (0.34–0.68)
PPV [% (95 % CI)] 68.63 (54.11–80.89) 86.96 (66.41–97.22) 61.22 (46.24–74.80) 100 (83.16–100) 62.22 (46.54–76.23) 95.00 (75.13–99.87)
NPV [% (95 % CI)] 97.14 (85.08–99.93) 74.60 (62.06–84.73) 83.78 (67.99–93.81) 75.76 (63.64–85.46) 80.49 (65.13–91.18) 74.24 (61.99–84.22)
Youden index 0.652 0.496 0.453 0.556 0.438 0.508
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The RT-PCR had the best performance in specificity, 
Positive likelihood ratio and positive predictive value 
in our present findings. However, it has lower sensitiv-
ity compared with NASBA-ELISA, indicating that the 
amplification efficiency of PCR is lower than NASBA as 
they all using the same RNA template. Lacking of stand-
ardization of PCR leaded to the failure to include DNA 
detection being incorporated into the EORTC/MSG cri-
teria for the definition of invasive fungal infection.
The NASBA-ELISA was proved the most sensitive 
assay and had the best performance in negative predictive 
value, Youden index, and К value in our present findings. 
The high sensitivity of NASBA-ELISA is probably since 
that NASBA possesses a higher inherent amplification 
capability than RT-PCR because each cDNA template 
produces numerous RNA copies per cycle in the former 
technique while each cDNA merely doubles in number at 
each cycle in the latter. Further more, the detection pro-
cedure is conducted with enzyme-linked immunosorbent 
assay of DIG-labeled NASBA amplicons. NASBA is bet-
ter to reveal IA infection status since the RNA template of 
NASBA amplification is closely related to active microbes. 
Since the NASBA assay only allows amplification of tem-
plate nucleic acids with T7 promoter and thermal dena-
turation is absent for NASBA, contaminating background 
of homologous DNA is not a problem. As an alternative 
technology to detect NASBA amplification products, 
ELISAs avoid subjective interpretations of amplification 
results due to “bands of unknown origin” or “nonspecific 
products” among other features and can detect batch of 
samples automatically. Moreover, though NASBA-ELISA 
is a technique of end-point amplification products analy-
sis, it also allows for quantification in a certain range of 
original RNA concentrations that cover all the significant 
amount of Aspergillus in clinical samples.
In this study, we developed a simple quantitative micro-
plate hybridization method for detection of NASBA 
products and evaluated its performance by plasma sam-
ple of patients at high risk for IA. The results exhibited 
that NASBA-ELISA has several advantages such as high 
sensitivity, good specificity (absence of cross-reactivity 
with other unrelated bacteria or fungus) and can be eas-
ily performed. It can analyze a numbers of samples simul-
taneously without any special instrument and reasonably 
it may be particularly useful for routine purposes in less 
developed laboratories. Combining NASBA-ELISA with 
other techniques can improve the diagnostic accuracy and 
could be particularly useful in specific clinical situations.
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